Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels

Digestive and Liver Disease

Volumn 40, Issue 9, 2008, Pages 785-790

  Lenci, I ^a   Piccolo, P ^a   Francioso, S ^a   Di Paolo, D ^a   Galante, A ^a   Angelico, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antiviral therapy; Myocardial ischaemia; PNALT

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CLINICAL PROTOCOL; CORONARY ARTERY SPASM; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HEPATITIS C; HUMAN; MALE; MOTIVATION; RELAPSE; SYNCOPE; VIROLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYOCARDIAL ISCHEMIA; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 48149093105     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.03.010     Document Type: Article

References (21)

1. Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36 Suppl 1 (2002) S179-S184
2. Serfaty L., Chazouilleres O., Pawlotsky J.M., Andreani T., Pellet C., and Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 110 (1996) 291-295
3. Nutt A.K., Hassan H.A., Linndsey J., Lamps L.W., and Raufman J.P. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near normal serum alanine aminotransferase. Am J Med 109 (2000) 62-64
4. Puoti C., Bellis L., Martellino F., Guarisco R., Dell' Unto O., Durola L., et al. Chronic hepatitis C and normal ALT levels: treat the disease not the test. J Hepatol 43 (2005) 534-535
5. Alberti A., Noventa F., Benvegnu L., Boccato S., and Gatta A. Prevalence of liver disease in a population of asymptomatic person with hepatitis C virus infection. Ann Intern Med 137 (2002) 961-964
6. Gholson C.F., Morgan K., Catinis G., Favrot D., Taylor B., Gonzalez E., et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 92 (1997) 1788-1792
7. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alpha 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 140 (2004) 346-355
9. Zeuzem S., Diago M., Gane E., Reddy R., Pockros P., Prati D., et al., The Pegasys Study NR16071 Investigator Group. Peginterferon alpha 2a (40 Kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732
10. National Institute of Health. National Institute of Heath Consensus Development Conference Statement: management of hepatitis C: 2002 June 10-12. Hepatology 36 (2002) S3-S20
11. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
12. Persico M., Persico E., Suozzo R., Conte S., De Seta M., Coppola L., et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118 (2000) 760-764
13. Cividini A., Rebucci C., Silini E., and Mondelli M.U. Is the natural history of HCV carriers with normal aminotransferase levels really benign?. Gastroenterology 121 (2001) 1526-1527
14. Mathurin P., Moussalli J., Cadranel J.F., Thibault V., Charlotte F., Dumouchel P., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27 (1998) 868-872
15. Hui C.K., Belaye T., Montegrande K., and Wright T.L. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38 (2003) 511-517
16. Vassalle C., Masini S., Bianchi F., and Zucchelli G.C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90 (2004) 565-566
17. Ishizaka Y., Ishizaka N., Takahashi E., Unuma T., Tooda E., Hashimoto H., et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67 (2003) 26-30
18. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E., Hashimoto H., Nagai R., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359 (2002) 133-135
19. Kiechl S., Egger G., Mayr M., Wiedermann C.J., Bonora E., Oberhollenzer F., et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103 (2001) 1064-1070
20. Arcari C.M., Nelson K.E., Netski D.M., Nieto F.J., and Gaydos C.A. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 43 (2006) e53-e56
21. Danesh J., Collins R., and Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 350 (1997) 430-436